Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to β-Lactam Antibiotics | Zendy

Samira Dahesh | Zendy; Mary E. Hensler | Zendy; Nina M. van Sorge | Zendy; Robert E. Gertz | Zendy; Stephanie J. Schrag | Zendy; Victor Nizet | Zendy; Bernard Beall | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Point Mutation in the Group B Streptococcal pbp2x Gene Conferring Decreased Susceptibility to β-Lactam Antibiotics

Author(s) -

Samira Dahesh,

Mary E. Hensler,

Nina M. van Sorge,

Robert E. Gertz,

Stephanie J. Schrag,

Victor Nizet,

Bernard Beall

Publication year - 2008

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00461-08

Subject(s) - complementation , biology , antibiotics , microbiology and biotechnology , genetics , mutation , group b , point mutation , gene , group a , beta lactam , mutant , medicine

Beta-lactam antibiotics (BLAs) are the first-line agents used against group B streptococci (GBS) infection. A clonal set of four independent, invasive GBS isolates with elevated MICs to BLAs were identified that shared apbp2x mutation (Q557E) corresponding to a resistance-conferring pneumococcal mutation. BLA sensitivity was restored through allelic replacement or complementation with the wild-typepbp2x .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research